Burden of illness of bone metastases in prostate cancer patients in Québec, Canada: A population-based analysis

Journal of the Canadian Urological Association

Volumn 9, Issue 9-10 October, 2015, Pages 307-314

  Perrault, Louise ^a   Fradet, Vincent ^b   Lauzon, Véronique ^a   Lelorier, Jacques ^c   Mitchell, Dominic ^a   Habib, Mohdhar ^d  

^a International Market Access Consulting   (Switzerland)

^b Université Laval   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d Amgen Canada Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84944239930     PISSN: 19116470     EISSN: 19116470     Source Type: Journal    
DOI: 10.5489/cuaj.2707     Document Type: Article

References (27)

1. Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2014. Toronto, ON: Canadian Cancer Society; 2014.
2. Saad F, Clarke N, Colombel M. Natural history and treatment of bone complications in prostate cancer. Eur Urol 2006;49:429-40. http://dx.doi.org/10.1016/j.eururo.2005.12.045
3. Luz MA, Aprikian AG. Preventing bone complications in advanced prostate cancer. Curr Oncol 2010;17:S65-71.
4. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s-9s. http://dx.doi.org/10.1158/1078-0432.CCR-06-0931
5. Sathiakumar N, Delzell E, Morrisey MA, et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: A population-based analysis of US Medicare beneficiaries, 1999-2006. Prostate Cancer Prostatic Dis 2011;14:177-83. http://dx.doi.org/10.1038/pcan.2011.7
6. Delea T, McKiernan J, Brandman J, et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 2006;4:341-7.
7. Lage MJ, Barber BL, Harrison DJ, et al. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008;14:317-22
8. Pockett RD, Castellano D, McEwan P, et al. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care (Engl) 2010;19:755-60. http://dx.doi.org/10.1111/j.1365-2354.2009.01135.x
9. Hagiwara M, Oglesby A, Chung K, et al. The impact of bone metastases and skeletal-related events on healthcare costs in prostate cancer patients receiving hormonal therapy. Community Oncol 2011;8:508-15
10. Oglesby A, Pockett RD, McEwan P, et al. Hospital burden of disease associated with metastatic bone disease (MBD) and skeletal-related events (SREs) in patients with breast cancer (BC) and prostate cancer (PC) in the United Kingdom (UK) [Abstract presented at the 11th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Athens, Greece, 8-11 November 2008] Value Health 2008;11:A476
11. Barlev A, Song X, Ivanov B, et al. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm 2010;16:693-702.
12. Mahmood A, Ghazal H, Fink MG, et al. Health-resource utilization attributable to skeletal-related events in patients with advanced cancers associated with bone metastases: Results of the US cohort from a multicenter observational study. Community Oncol 2012;9:148-57.
13. Schulman KL, Kohles J. Economic burden of metastatic bone disease in the U.S. Cancer 2007;109:2334-42.
14. Groot MT, Boeken Kruger CG, Pelger RC, et al. Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol 2003;43:226-32. http://dx.doi.org/10.1016/S0302-2838(03)00007-1
15. Seal B, Sullivan SD, Ramsey SD, et al. Comparing hospital-based resource utilization and costs for prostate cancer patients with and without bone metastases. Appl Health Econ Health Policy 2014;12:547-57. http://dx.doi.org/10.1007/s40258-014-0101-1
16. Habib MJ, Merali T, Mills A, et al. Canadian health care institution resource utilization resulting from skeletalrelated events. Hosp Pract (1995) 2014;42:15-22. http://dx.doi.org/10.3810/hp.2014.02.1087
17. Dragomir A, Dinea D, Vanhuyse M, et al. Drug costs in the management of metastatic castration-resistant prostate cancer in Canada. BMC Health Serv Res 2014;14:252. http://dx.doi.org/10.1186/1472-6963-14-252
18. Tamblyn R, Lavoie G, Petrella L, et al. The use of prescription claims databases in pharmacoepidemiological research: The accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995;48:999-1009.
19. Levy AR, Tamblyn RM, Fitchett D, et al. Coding accuracy of hospital discharge data for elderly survivors of myocardial infarction. Can J Cardiol 1999;15:1277-82.
20. Tamblyn R, Reid T, Mayo N, et al. Using medical services claims to assess injuries in the elderly: Sensitivity of diagnostic and procedure codes for injury ascertainment. J Clin Epidemiol 2000;53:183-94
21. Monfared AA, Lelorier J. Accuracy and validity of using medical claims data to identify episodes of hospitalizations in patients with COPD. Pharmacoepidemiol Drug Saf 2006;15:19-29.
22. Birnbaum HG, Cremieux PY, Greenberg PE, et al. Using healthcare claims data for outcomes research and pharmacoeconomic analyses. Pharmacoeconomics 1999;16:1-8.
23. Institut national de santé publique. Utilisation du fichier des paiements a l’acte de la RAMQ pour identifier les cas de cancers non déclarés au Fichier des tumeurs du Québec, Etude de faisabilité – Volet: Cancer de la prostate, Institue National de santé public du Québec, Février 2006. [updated 2006 Feb; cited 2013 Aug 5]. http://www.inspq.qc.ca/pdf/publications/488-CancersNonDeclareFichiersTumeurs.pdf. Accessed January 16, 2015
24. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203. http://dx.doi.org/10.1016/0895-4356(92)90016-G
25. Statistics Canada. CANSIM Table 326-0020: Consumer Price Index (CPI), 2011 basket
26. Pozen A, Cutler DM. Medical spending differences in the United States and Canada: The role of prices, procedures, and administrative expenses. Inquiry 2010;47:124-34
27. Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA Guideline. J Urol 2013;190:429-38. http://dx.doi.org/10.1016/j.juro.2013.05.005